TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
According to the terms of the agreement, TriLink will supply its patented CleanCap® M6, CleanCap® AG 3'OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Aldevron's mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap® technology produces optimal 5'Cap structures with over 95% efficiency, creating a co-transcriptional capping solution that improves mRNA yield and process time when compared to legacy capping methods.
'CleanCap technology is accelerating programs through drug development milestones and has been the capping technology of choice for mRNA constructs in 350+ preclinical and clinical programs,' shared Becky Buzzeo, Chief Commercial Officer, Maravai. 'We're excited to offer our innovative capping solutions to Aldevron and its manufacturing customers.'
Since its launch in 2017, TriLink's CleanCap® capping technology has continued to advance the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap® analog to date, CleanCap® M6, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods.
Aldevron, based in Fargo, ND, is a leader in advancing biological science. Their custom development and manufacturing services provide scientists with essential components to accelerate research and breakthrough discoveries.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders to enabling future pandemic response plans.
For more information, visit trilinkbiotech.com.
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit maravai.com.
About Aldevron
Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, RNA, proteins, enzymes, and other key components for the development of vaccines, gene and cell therapies, immunotherapies, and other treatments. Headquartered in Fargo, North Dakota, and as a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. To learn more about how Aldevron is advancing biological science, visit www.aldevron.com.
Liz Robinson of CG Life
TriLink BioTechnologies
+1 312-997-2436
[email protected] Shafer
Senior Director of Communications
Aldevron
O: 701-551-8704
[email protected] contact:
Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
SOURCE: TriLink BioTechnologies
Copyright Business Wire 2025.
PUB: 02/04/2025 04:01 PM/DISC: 02/04/2025 04:02 PM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 minutes ago
- Business Wire
MedX Health Corp. Names Meghan Geary as Senior Vice President of Operations
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of Meghan Geary as the Company's Senior Vice President of Operations, effective immediately. With over 10 years experience in building scalable programs across SaaS and high-growth healthcare companies, Geary will oversee strategic operations, drive organization performance, and support MedX's continued growth trajectory. "I'm excited to join MedX at such a pivotal stage of its journey," said Geary. "Throughout my career, I've focused on scaling programs that streamline processes and promote cross-functional alignment. I look forward to collaborating with the MedX team to optimize operations and ensure the Company is positioned for long-term success." The Company's CEO, John Gevisser added: 'Meghan brings formidable experience to MedX at a time when we are scaling operations across different markets. Having previously worked closely with her, I understand what a vital asset to our team she is. Her ability to lead strategic programs, adjust and direct processes and improve organizational performance will play a central role in our next phase of growth. Meghan critically understands that our deep and dynamic image store is central to our AI and SaaS strategy.' About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy ® technology, integrated into the DermSecure ® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared for use in 38 countries including by Health Canada, the U.S. Food and Drug Administration ('FDA'), the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX's advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy ®, and its secure, cloud-based patient management system, DermSecure ®. SIAscopy® is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin's surface. Visit: https// This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Yahoo
32 minutes ago
- Yahoo
If You Buy O'Reilly Automotive With $10,000 in 2025, Will You Become a Millionaire in 10 Years?
Key Points O'Reilly will continue to benefit from the aging vehicle fleet, which requires more maintenance. The company sees strong demand regardless of the macro climate, reducing risk for shareholders. Shares trade at a historically expensive valuation, which limits the upside for returns. 10 stocks we like better than O'Reilly Automotive › O'Reilly Automotive (NASDAQ: ORLY) isn't an exciting business by any stretch of the imagination. In fact, this might be one of the most boring companies on the planet. It sells aftermarket auto parts to DIY and professional customers through physical stores. That's not a page-turning operational description. However, this retail stock's performance will get you up off your seat and cheering in no time. Over the past 30 years, shares have soared 42,650% (as of Aug. 15). An investment of $2,350 back then would be worth $1 million today. But if you were to buy $10,000 worth of O'Reilly stock in 2025, will you become a millionaire in 10 years? O'Reilly's bullish case O'Reilly's fantastic return comes from the fact that this is a great company. And I believe there are some key reasons why it's so great, all of which support the stock's bull case. For starters, O'Reilly benefits from durable industry tailwinds. The average age of cars on the road in the U.S. is now 12.5 years. It has steadily increased over the past two and a half decades. As these vehicles age and get past their original warranty, consumers must spend money on aftermarket parts to keep them in working condition. What's more, the number of cars on the road continues to increase. These long-lasting trends support O'Reilly's long-term growth prospects. Revenue rose at a compound annual rate of 8.3% in the past decade. And the business continues to open new stores, with 200 to 210 planned just in 2025. Another reason this is a high-quality business is the consistent demand that O'Reilly sees throughout an economic cycle. In strong economic times, when consumer confidence and spending are robust, people tend to drive more. This increases the wear and tear on their vehicles. As a result, there is a clear need for the parts and supplies O'Reilly stores sell. When a recession hits, unemployment rises, and consumers pull back on their spending, they certainly delay buying new vehicles. However, they still need their existing cars to work. This setup incentivizes spending on maintenance and upgrades. Again, O'Reilly benefits. Being able to perform well from a fundamental perspective in good and bad times makes O'Reilly an attractive investment. Nothing stands out quite like the fact that 2025 is shaping up to be the company's 33rd straight year of same-store sales growth. That's an unbelievable track record. Investors will also appreciate the management team's capital allocation policy. Because of O'Reilly's consistent profitability, it's left with excess cash. Executives have plowed this money into stock buybacks, which have helped reduce the diluted outstanding share count by 3.1% in the past year alone. Waiting for a 100-fold jump For this stock to turn a $10,000 investment into $1 million, its price would need to register a 100-fold rise. This might have been how O'Reilly shares performed in the past. However, it's not a realistic outcome as we look toward the future. And it definitely won't happen in the next decade. In fact, investors shouldn't bet the house on any single company helping them reach a $1 million portfolio balance. This outstanding business could continue to post double-digit earnings-per-share growth on a yearly basis. But it's at a much more mature stage of its lifecycle these days. Expecting the stock price to rise 100-fold is irrational. That doesn't mean O'Reilly doesn't deserve a place on your watch list. While the stock looks historically expensive at its current price-to-earnings ratio of 36.4, investors can wait for a pullback before scooping up shares. Do the experts think O'Reilly Automotive is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did O'Reilly Automotive make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,055% vs. just 183% for the S&P — that is beating the market by 871.03%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,076,588!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Neil Patel has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. If You Buy O'Reilly Automotive With $10,000 in 2025, Will You Become a Millionaire in 10 Years? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Pure Storage (PSTG) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Pure Storage (PSTG) closed at $55.53 in the latest trading session, marking a -2.95% move from the prior day. This change lagged the S&P 500's daily loss of 0.24%. Meanwhile, the Dow gained 0.04%, and the Nasdaq, a tech-heavy index, lost 0.67%. Heading into today, shares of the data storage company had gained 2.54% over the past month, outpacing the Computer and Technology sector's gain of 2.07% and the S&P 500's gain of 1.95%. Investors will be eagerly watching for the performance of Pure Storage in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 27, 2025. The company is predicted to post an EPS of $0.4, indicating a 9.09% decline compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $845.76 million, up 10.74% from the prior-year quarter. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $1.82 per share and revenue of $3.52 billion. These totals would mark changes of +7.69% and +11.01%, respectively, from last year. It's also important for investors to be aware of any recent modifications to analyst estimates for Pure Storage. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. At present, Pure Storage boasts a Zacks Rank of #3 (Hold). In terms of valuation, Pure Storage is presently being traded at a Forward P/E ratio of 31.47. This indicates a premium in contrast to its industry's Forward P/E of 14.11. Meanwhile, PSTG's PEG ratio is currently 1.69. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. PSTG's industry had an average PEG ratio of 1.69 as of yesterday's close. The Computer- Storage Devices industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 27, finds itself in the top 11% echelons of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pure Storage, Inc. (PSTG) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
